Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)

Shanghai Shyndec Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	11,389	11,787	12,810	13,756	12,408	12,051
Other Revenue	196.12	282.98	149.79	189.06	147.99	148.54
Revenue	11,585	12,070	12,959	13,945	12,556	12,199
Revenue Growth (YoY)	-11.00%	-6.86%	-7.07%	11.06%	2.93%	7.76%
Cost of Revenue	7,201	7,538	8,091	7,909	6,765	6,239
Gross Profit	4,385	4,532	4,868	6,036	5,791	5,960
Selling, General & Admin	2,383	2,906	3,414	4,220	4,049	4,268
Research & Development	561.1	562.24	517.14	584.97	493.67	412.76
Other Operating Expenses	112.49	115.06	113.17	128.31	127.33	134.16
Operating Expenses	3,024	3,565	4,027	4,958	4,696	4,822
Operating Income	1,361	967.35	841.24	1,078	1,095	1,138
Interest Expense	-38.83	-57.88	-107.31	-110.47	-123.51	-189.44
Interest & Investment Income	158.63	136.48	61.69	48.84	36.78	51.65
Currency Exchange Gain (Loss)	25.14	28.44	98.32	-32.65	-64.01	21.74
Other Non Operating Income (Expenses)	-19.6	-4.09	-4.23	-5.75	-9.6	-10.17
EBT Excluding Unusual Items	1,486	1,070	889.71	978	934.57	1,012
Impairment of Goodwill	-	-	-	-132.15	-44.76	-
Gain (Loss) on Sale of Investments	11.86	-	-	-24.04	-21.81	-42.81
Gain (Loss) on Sale of Assets	-33.52	-31.85	-1.1	0.2	23.92	-14.57
Asset Writedown	-12.25	-13.66	-4.93	-10.81	-4.5	-0.75
Other Unusual Items	113.21	71.77	100.45	107	153.7	119.07
Pretax Income	1,565	1,097	984.12	918.21	1,041	1,073
Income Tax Expense	228.42	131.95	116.63	97.06	141.08	144.39
Earnings From Continuing Operations	1,337	964.61	867.48	821.15	900.05	928.47
Minority Interest in Earnings	-271.56	-272.73	-239.69	-252.87	-251.25	-272.1
Net Income	1,065	691.88	627.79	568.28	648.79	656.37
Net Income to Common	1,065	691.88	627.79	568.28	648.79	656.37
Net Income Growth	42.46%	10.21%	10.47%	-12.41%	-1.15%	-6.97%
Shares Outstanding (Basic)	1,341	1,273	1,027	1,027	1,027	1,051
Shares Outstanding (Diluted)	1,341	1,273	1,156	1,178	1,179	1,152
Shares Change (YoY)	12.95%	10.13%	-1.82%	-0.14%	2.42%	5.45%
EPS (Basic)	0.79	0.54	0.61	0.55	0.63	0.62
EPS (Diluted)	0.79	0.54	0.54	0.48	0.55	0.57
EPS Growth	26.12%	0.07%	12.52%	-12.29%	-3.49%	-11.78%
Free Cash Flow	2,332	1,363	2,548	1,158	1,182	866.32
Free Cash Flow Per Share	1.74	1.07	2.20	0.98	1.00	0.75
Dividend Per Share	0.200	0.100	0.100	0.100	0.100	0.100
Dividend Growth	100.00%	0%	0%	0%	0%	0%
Gross Margin	37.85%	37.55%	37.57%	43.28%	46.12%	48.86%
Operating Margin	11.75%	8.01%	6.49%	7.73%	8.72%	9.33%
Profit Margin	9.20%	5.73%	4.84%	4.08%	5.17%	5.38%
Free Cash Flow Margin	20.13%	11.29%	19.66%	8.31%	9.42%	7.10%
EBITDA	2,150	1,766	1,671	1,857	1,821	1,861
EBITDA Margin	18.56%	14.63%	12.90%	13.31%	14.51%	15.25%
D&A For EBITDA	789.27	798.51	830.01	778.52	726.41	722.4
EBIT	1,361	967.35	841.24	1,078	1,095	1,138
EBIT Margin	11.75%	8.01%	6.49%	7.73%	8.72%	9.33%
Effective Tax Rate	14.59%	12.03%	11.85%	10.57%	13.55%	13.46%
Revenue as Reported	11,585	12,070	12,959	13,945	12,556	12,199
Advertising Expenses	-	4.64	3.29	7.1	6.43	7.59

Source: S&P Capital IQ. Standard template. Financial Sources.